Skip to main content

Table 2 Development of inflammation and disease activity in cases, controls and the remainder of the RABBIT cohort stratified by enrolment therapy

From: Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis

 

Treatment at baseline

Number

Mean at baseline (95 % CI)

Mean at month 3 (95 % CI)

Mean at month 6 (95 % CI)

CRP (mg/L)

Cases

csDMARD

37

21.6 (12.4; 30.8)

16.3 (9.0; 23.6)

14.3 (7.3; 21.2)

bDMARD

75

24.4 (18.2; 30.6)

19.5 (14.5; 24.5)

19.4 (13.5; 25.4)

Controls

csDMARD

40

10.2 (6.1; 14.3)

9.8 (5.1; 14.5)

8.0 (4.7; 11.3)

bDMARD

72

20.0 (14.1; 25.9)

11.4 (7.4; 15.4)

11.0 (6.9; 15.0)

Cohort remainder

csDMARD

3656

14.1 (13.5; 14.8)

11.4 (10.8; 11.9)

11.0 (10.4; 11.5)

bDMARD

7403

20.75 (20.1; 21.4)

12.9 (12.4; 13.3)

12.7 (12.2; 13.1)

ESR (mm/h)

Cases

csDMARD

37

30.4 (23.9; 36.9)

27.7 (20.9; 34.5)

31.4 (23.8; 39.0)

bDMARD

75

43.2 (35.9; 50.4)

36.8 (30.5; 43.2)

34.7 (28.7; 40.7)

Controls

csDMARD

40

26.8 (20.2; 33.4)

22.4 (16.5; 28.2)

19.4 (13.1; 25.7)

bDMARD

72

32.8 (28.1; 37.5)

22.7 (18.4; 27.1)

22.6 (18.8; 26.4)

Cohort remainder

csDMARD

3656

27.4 (26.7; 28.0)

23.9 (23.3; 24.5)

23.5 (22.8; 24.2)

bDMARD

7403

33.3 (32.7; 33.8)

24.4 (24.0; 24.9)

24.4 (24.0; 25.0)

DAS28

     

Cases

csDMARD

37

5.2 (4.8; 5.5)

4.0 (3.5; 4.4)

3.9 (3.4; 4.3)

bDMARD

75

5.8 (5.5; 6.1)

4.6 (4.2; 5.0)

4.6 (4.2; 5.0)

Controls

csDMARD

40

4.8 (4.4; 5.3)

4.0 (3.6; 4.5)

3.5 (3.0; 4.0)

bDMARD

72

5.9 (5.6; 6.1)

4.1 (3.7; 4.4)

3.9 (3.6; 4.3)

Cohort remainder

csDMARD

3656

4.8 (4.7; 4.8)

3.8 (3.7; 3.8)

3.7 (3.6; 3.7)

bDMARD

7403

5.4 (5.4; 5.5)

4.0 (3.9; 4.0)

3.9 (3.8; 3.9)

  1. Mean values are averaged over five imputations and CI were corrected for the imputation variance
  2. CI confidence interval, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, bDMARD biologic disease-modifying antirheumatic drug, csDMARD conventional synthetic DMARD